The Report “EpiCast Report: Chronic
Lymphocytic Leukemia – Epidemiology Forecast to 2023″ by Globaldata Group is
now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “EpiCast Report: Chronic Lymphocytic
Leukemia – Epidemiology Forecast to 2023″ in subject line and your contact
details to purchase this report or get your questions answered.
Summary
Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid
leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL
affects a particular lymphocyte, the B cell, which accumulates mainly in the
bone marrow and blood, and normally fights infection.
CLL is the most common form of leukemia in the western world, with
an average annual incidence of 5.0 per 100,000 population in people of all
ages. CLL is primarily a disease of the elderly population, with less than 10%
of the cases below 40 years of age.
Epidemiologists forecast an increase in the diagnosed incident cases
of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683
diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09%
during the forecast period. The 5-year diagnosed prevalent cases of CLL in the
6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165
diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast
period.
Epidemiological forecast for the diagnosed incident and 5-year
diagnosed prevalent cases of CLL in the 6MM is supported by age- and
sex-specific data for incidence and 1- to 5-year relative survival data used
for the 5-year diagnosed prevalent cases forecast are supported by
country-specific, population-based studies that are nationally representative
of the entire population in the respective markets. The diagnosed incident
cases of CLL in each of the 6MM were further segmented by Rai stage at
diagnosis to provide a more detailed analysis of the patient population, as Rai
stage at diagnosis is an important factor for predicting the prognosis and
treatment modalities for CLL at different stages.
Request Sample copy of this
report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=173920 .
Scope
- The Chronic lymphocytic leukemia (CLL) EpiCast Report provides
an overview of the risk factors, comorbidities, and the global and historical
trends for CLL in the six major markets (6MM) (US, France, Germany, Italy,
Spain, and UK). In addition, the report also includes a 10-year epidemiological
forecast of the diagnosed incident cases of CLL segmented by age (beginning at
40 years and ending at 80 years and older) and sex. Epidemiologists also
forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally,
the report provides CLL diagnosed incident cases segmented by Rai stage at
diagnosis for the 6MM.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
- The CLL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping
and driving the global CLL market.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.
- Quantify patient populations in the global CLL market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for CLL therapeutics in each of the markets covered.
Complete
report is available @ http://www.rnrmarketresearch.com/epicast-report-chronic-lymphocytic-leukemia-epidemiology-forecast-to-2023-market-report.html .
Table of Contents
1
Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Survival from CLL - US and 5EU 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases 19
3.4.4 Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases 21
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Survival from CLL - US and 5EU 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 17
3.4.2 Sources Not Used 19
3.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases 19
3.4.4 Forecast Assumptions and Methods, 5-Year Diagnosed Prevalent Cases 21
For further information on “EpiCast Report: Chronic Lymphocytic Leukemia – Epidemiology Forecast to
2023” report OR for any other business research / market intelligence
need on the ‘pharmaceuticals’ market
(http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals . ),
contact sales@rnrmarketresearch.com /
Call +1 888 391 5441.
About Us:
RnRMarketResearch.com is an online market research
reports library of 250,000+ in-depth studies of over 5000 micro markets. Our
database includes reports by leading publishers from across the globe. We
provide 24/7 online and offline support service to our customers. RnR Market
Research also offers company data, country profiles, trends, information and
analysis on the sector of your interest.
You
can also reach us @
No comments:
Post a Comment
Note: only a member of this blog may post a comment.